QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NASDAQ:AGIO

Agios Pharmaceuticals Stock Forecast, Price & News

$45.84
-2.20 (-4.58 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$45.76
Now: $45.84
$48.57
50-Day Range
$33.21
MA: $42.42
$49.50
52-Week Range
$27.77
Now: $45.84
$56.74
Volume753,427 shs
Average Volume817,937 shs
Market Capitalization$3.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Agios Pharmaceuticals logo

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

356th out of 1,926 stocks

Pharmaceutical Preparations Industry

189th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600
Employees536
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share

Profitability

Net Income$-411,470,000.00
Net Margins-170.65%

Miscellaneous

Market Cap$3.17 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$45.84
-2.20 (-4.58 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGIO shares have increased by 12.2% and is now trading at $45.84.
View which stocks have been most impacted by COVID-19
.

Is Agios Pharmaceuticals a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Agios Pharmaceuticals stock.
View analyst ratings for Agios Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Agios Pharmaceuticals?

Wall Street analysts have given Agios Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Agios Pharmaceuticals
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.36) by $0.07. The biopharmaceutical company had revenue of $34.70 million for the quarter, compared to the consensus estimate of $38.12 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 57.63% and a negative net margin of 170.65%. The business's revenue for the quarter was up 33.5% compared to the same quarter last year. During the same quarter last year, the company earned ($1.81) earnings per share.
View Agios Pharmaceuticals' earnings history
.

What price target have analysts set for AGIO?

11 brokerages have issued twelve-month price objectives for Agios Pharmaceuticals' stock. Their forecasts range from $50.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $67.64 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Dr. Jacqualyn A. Fouse, CEO & Director (Age 60, Pay $1.25M)
  • Mr. Jonathan Biller J.D., CFO and Head of Legal & Corp. Affairs (Age 57, Pay $150.52k)
  • Dr. Scott A. Biller, Strategic Advisor (Age 65, Pay $687.56k)
  • Dr. Christopher J. Bowden, Chief Medical Officer (Age 60, Pay $701.63k)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 72)
  • Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 75)
  • Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 68)
  • Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 65)
  • Ms. Carman Alenson, Principal Accounting Officer and VP of Accounting, Treasury & Tax
  • Dr. Clive Patience, Exec. VP of Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.35%), Rhenman & Partners Asset Management AB (0.19%), Pacer Advisors Inc. (0.01%), Sowell Financial Services LLC (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals
.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and Nisa Investment Advisors LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Sowell Financial Services LLC, and Pacer Advisors Inc.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $45.84.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.17 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 536 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.